Corvus Pharmaceuticals, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This annual filing also reports unaudited fourth-quarter results. Corvus is a clinical-stage biopharmaceutical company with no product-sales revenue; its pipeline focuses on immunology-based candidates for COVID-19, cancers and autoimmune diseases.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $31.8 million | $38.0 million |
| General and administrative expense | $11.9 million | $10.9 million |
| Total operating expenses / operating loss | $43.8 million / $(43.8) million | $48.9 million / $(48.9) million |
| Net loss | $(6.0) million | $(46.7) million |
| Net loss per share | $(0.20) | $(1.59) |
| Cash, cash equivalents and marketable securities at year-end | $44.3 million | $78.0 million |
| Working capital at year-end | $33.2 million | $69.1 million |
| Net cash used in operating activities | $(34.8) million | $(37.3) million |
2020 net loss included a non-cash $37.5 million gain from deconsolidating Angel Pharmaceuticals, partly offset by a $0.2 million equity-method investment loss. The gain reduced the reported annual loss but did not represent operating revenue or cash generated from operations. Fourth-quarter results included $27.3 million of net income, or $0.92 per share, alongside $9.9 million of operating expenses, principally reflecting the Angel gain.
Research and development expense declined by $6.1 million year over year, while general and administrative expense rose by $1.1 million. The company reported no product revenue and remained loss-making from operations; profit margins are therefore not meaningful. Total liabilities were $13.4 million, including operating lease liabilities; the filing reports no material borrowings. Lease obligations totaled $2.6 million, primarily due in 2021 and 2022.
Operating cash use remained substantial. Cash and cash equivalents increased to $16.5 million from $5.2 million, while marketable securities declined to $27.8 million from $72.8 million, reflecting the investment portfolio’s maturities, purchases and sales. At year-end, Corvus had $48.7 million of remaining capacity under its at-the-market stock sale agreement. On February 17, 2021, it raised approximately $31.8 million net in a follow-on offering. Management said available resources, including those proceeds, were expected to fund planned operations for at least 12 months from the financial statements’ issuance date; it also stated that existing resources would not fund all development through commercialization.
Business, pipeline and material developments
- CPI-006: In February 2021, Corvus initiated a global, randomized, double-blind Phase 3 trial in approximately 1,000 hospitalized patients with mild-to-moderate COVID-19. The primary endpoint is progression to respiratory failure or death within 28 days; enrollment completion was expected in the fourth quarter of 2021. In a 29-patient Phase 1 study, the company reported no drug-related toxicities and observed antibody responses, but these early findings do not establish efficacy. The company paused further enrollment in its oncology trial to prioritize COVID-19 development.
- CPI-818: The candidate is in a Phase 1/1b trial for T-cell lymphomas. Preliminary results included responses in a small number of evaluable patients and no dose-limiting toxicities or Grade 3 or 4 treatment-related adverse events reported as of the stated cutoff. Corvus and Angel planned a global Phase 2 study in peripheral T-cell lymphoma.
- Ciforadenant: Earlier renal-cell-cancer studies reported activity, particularly in patients with a high adenosine gene-signature biomarker; the filing cites a 17% response rate in biomarker-positive patients. Corvus planned a roughly 60-patient front-line renal-cell-cancer Phase 2 study combining ciforadenant with pembrolizumab and lenvatinib. This was a plan, not an ongoing trial reported as initiated.
- Angel Pharmaceuticals: Corvus formed and financed the China-based company in 2020, licensing it greater-China rights to three clinical-stage candidates and global rights to preclinical BTK inhibitor programs. Corvus retained approximately 49.7% equity, excluding shares reserved for Angel’s employee plan. The transaction caused deconsolidation and the one-time accounting gain; the approximately $41 million investor funding went to Angel and was not available to Corvus.
Outlook, risks and contingencies
Corvus expects continued operating losses and significant research and development spending. Its key uncertainties include clinical-trial outcomes, regulatory approval, patient enrollment, manufacturing and supply dependencies, competition, intellectual-property protection and the need for additional financing. The COVID-19 pandemic could disrupt trial enrollment, sites, monitoring and supply chains; Corvus reported that its oncology trials had not been significantly affected to date, but future effects remained uncertain. The company relies on third parties for clinical trials and most manufacturing and has no commercial manufacturing capability.
Reported safety observations remain preliminary. The filing describes serious adverse events possibly or reportedly related to ciforadenant combination studies, including hemolytic anemia, encephalitis, hepatitis, pneumonitis and myocarditis. The company also cautions that larger or later-stage studies may identify risks not seen in earlier trials. Corvus reported no material legal proceedings, no off-balance-sheet arrangements and effective management assessments of disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness because of the company’s emerging-growth-company exemption.
Most important facts for investors to verify
- Progress, enrollment, safety findings and results of the CPI-006 Phase 3 trial, including whether the planned enrollment timeline was achieved.
- Corvus’s cash runway and financing needs, including the effect of the February 2021 offering, ATM share sales and future development spending.
- The accounting and valuation of the Angel investment, the rights licensed to Angel, and whether Angel can execute its development plans.
- Whether preliminary CPI-818 and ciforadenant findings are confirmed in larger studies, and whether planned trials proceed.
- Potential dilution from equity financing and stock-based awards, and the status and enforceability of relevant intellectual-property rights.